-
公开(公告)号：US5877158A
公开(公告)日：1999-03-02
申请号：US309035
申请日：1994-09-20
申请人： Klaus Bosslet , Jorg Czech , Dieter Hoffmann , Fran.cedilla.ois Tillequin , Jean-Claude Florent , Michel Azoulay , Claude Monneret , Jean-Claude Jacquesy , Jean-Pierre Gesson , Michel Koch
发明人： Klaus Bosslet , Jorg Czech , Dieter Hoffmann , Fran.cedilla.ois Tillequin , Jean-Claude Florent , Michel Azoulay , Claude Monneret , Jean-Claude Jacquesy , Jean-Pierre Gesson , Michel Koch
IPC分类号： C07H15/244 , A61K31/70 , A61K31/7028 , A61K31/7034 , A61K31/704 , A61K47/48 , A61P43/00
CPC分类号： B82Y5/00 , A61K47/48092 , A61K47/48192 , A61K47/48215 , A61K47/48223 , A61K47/48315 , A61K47/48761
摘要： Substrate-spacer-prodrug compounds (pro-prodrugs) suited for site specific delivery of drugs, a process of preparing them and their use are described.
摘要翻译： 描述了适合于药物的位点特异性递送的基质 - 间隔物前药化合物（前体前药），其制备方法及其应用。
-
42.发明授权Use of deoxyspergualin for preparing a pharmaceutical for treating hyperreactive inflammatory diseases 失效使用脱氧精球蛋白制备治疗高反应性炎性疾病的药物
公开(公告)号：US5849799A
公开(公告)日：1998-12-15
申请号：US406406
申请日：1995-03-20
IPC分类号： A61K9/12 , A61K31/16 , A61K31/164 , A61K31/4164 , A61P1/00 , A61P1/04 , A61P9/00 , A61P9/10 , A61P11/00 , A61P11/06 , A61P11/08 , A61P25/28 , A61P29/00 , A61P37/06 , A61K31/155 , A61K31/415
CPC分类号： A61K31/16
摘要： Methods are disclosed for treatment of hyperreactive inflammatory diseases of humans and animals comprising administering a pharmaceutically effective amount of deoxyspergualin to a human or an animal.
摘要翻译： 公开了用于治疗人和动物的高反应性炎性疾病的方法，包括向人或动物施用药学有效量的脱氧精胍菌素。
-
43.发明授权Gene therapy of tumors with an endothelial cell-specific, cell cycle-dependent active compound 失效具有内皮细胞特异性，细胞周期依赖性活性化合物的肿瘤的基因治疗
公开(公告)号：US5830880A
公开(公告)日：1998-11-03
申请号：US793107
申请日：1997-04-18
申请人： Hans-Harald Sedlacek , Klaus Bosslet , Rolf Muller
发明人： Hans-Harald Sedlacek , Klaus Bosslet , Rolf Muller
IPC分类号： C12N15/09 , A61K9/127 , A61K35/76 , A61K38/00 , A61K38/21 , A61K38/22 , A61K38/44 , A61K38/46 , A61K38/55 , A61K39/395 , A61K47/48 , A61K48/00 , A61P7/02 , A61P9/08 , A61P25/00 , A61P35/00 , A61P43/00 , C07K14/47 , C07K14/475 , C12N15/00 , C12N15/85 , C12P21/02 , C12R1/91 , C12R1/92 , C07H21/04
CPC分类号： A61K48/00 , C12N15/85 , A61K38/00 , C12N2830/15 , C12N2830/30 , C12N2830/85
摘要： A DNA sequence for the gene therapy of tumors is described. In its essential elements, the DNA sequence is composed of an activator sequence, a promoter module and a gene for the active substance. The activator sequence is activated, in a cell-specific manner, in proliferating endothelial cells or in cells which are adjacent to these endothelial cells. This activation is regulated by the promoter module in a cell cycle-specific manner. The active substance is an inhibitor of angiogenesis or a cytostatic or cytotoxic molecule. The DNA sequence is inserted into a viral or non-viral vector which is supplemented with a ligand which possesses affinity for the activated endothelial cell.
摘要翻译： PCT No.PCT / EP95 / 03370 Sec。 371日期1997年4月18日 102（e）1997年4月18日PCT PCT 1995年8月25日PCT公布。 出版物WO96 / 06940 日期1996年3月7日描述了肿瘤基因治疗的DNA序列。 在其基本元素中，DNA序列由活化物序列，启动子模块和活性物质的基因组成。 活化剂序列以细胞特异性方式在增殖的内皮细胞或与这些内皮细胞相邻的细胞中活化。 该激活由细胞周期特异性方式由启动子模块调节。 活性物质是血管发生抑制剂或细胞抑制或细胞毒性分子。 将DNA序列插入病毒或非病毒载体中，其补充有对活化的内皮细胞具有亲和力的配体。
-
44.发明授权Inhibitors of .beta.-glucuronidase and their use in the treatment of carcinamatosis and inflammation 失效β-葡萄糖醛酸苷酶的抑制剂及其在治疗癌症和炎症中的应用
公开(公告)号：US5817800A
公开(公告)日：1998-10-06
申请号：US904618
申请日：1997-08-01
申请人： Klaus Bosslet , Jorg Czech , Andrea Vasella , Roland Hoos
发明人： Klaus Bosslet , Jorg Czech , Andrea Vasella , Roland Hoos
IPC分类号： C07D309/28 , A61K31/35 , A61K31/351 , A61P29/00 , A61P35/00 , A61P43/00 , C07D211/78 , C07D309/30 , C07D335/02 , C07F9/59 , C07F9/655 , C07F9/6553 , C07H5/04 , C07H1/00 , A61K31/70
CPC分类号： C07D211/78 , C07D309/30 , C07D335/02 , C07F9/597 , C07F9/6552
摘要： Compounds of the formulae I and II ##STR1## are suitable for the suppression of tumor growth and of tumor metastasis.
摘要翻译： 式I和II的化合物（I）图像（II）适用于抑制肿瘤生长和肿瘤转移。
-
公开(公告)号：US5639621A
公开(公告)日：1997-06-17
申请号：US468661
申请日：1995-06-06
申请人： Klaus Bosslet , Peter Pfleiderer , Gerhard Seemann
发明人： Klaus Bosslet , Peter Pfleiderer , Gerhard Seemann
IPC分类号： A61B10/00 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , C07K14/47 , C07K16/00 , C07K16/18 , C07K16/30 , C07K19/00 , C12N5/10 , C12N5/20 , C12N5/22 , C12N15/02 , C12N15/09 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/577 , C12N5/12
CPC分类号： C07K14/47 , C07K16/18 , C07K16/30 , C07K16/3015 , C07K16/3038 , A61K38/00 , A61K39/00 , C07K2317/24 , C07K2319/00
摘要： The invention relates to monoclonal antibodies against a tumor-associated antigen which is mainly derived from tumors from the group of carcinomas of the breast, ovaries and prostate, as well as adenocarcinomas of the lung, which additionally react with polymorphic epithelial mucin (PEM), to the preparation and use thereof and to the use of the epitope defined by the antibody for diagnosis and therapy.
摘要翻译： 本发明涉及抗肿瘤相关抗原的单克隆抗体，其主要衍生自乳腺癌，卵巢和前列腺癌的肿瘤，以及另外与多形性上皮粘蛋白（PEM）反应的肺腺癌， 关于其制备和使用以及由抗体定义的表位用于诊断和治疗的用途。
-
46.发明申请Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof 失效针对肿瘤相关抗原的单克隆抗体（MAb），其制备和应用公开(公告)号：US20090246132A1
公开(公告)日：2009-10-01
申请号：US12068545
申请日：2008-02-07
IPC分类号： A61K51/10 , C07K16/18 , C12N9/00 , A61K39/395 , C07K19/00 , C07K16/46 , C12P21/02 , A61P35/00 , G01N33/53
CPC分类号： C07K16/3084 , A61K38/00 , A61K47/68 , A61K47/6815 , A61K47/6817 , A61K47/6851 , A61K51/1045 , C07K16/30 , C07K2317/24 , C07K2317/56 , C07K2317/76 , C07K2319/00 , C07K2319/30
摘要： The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or “humanized” MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
摘要翻译： 本发明涉及针对肿瘤相关抗原的鼠单克隆抗体（MAb），A，B，C和D。 描述了这些MAb的V基因的几乎完整的核苷酸序列，使得相关的可变结构域可以放在一起以产生嵌合的MAb，或者通过将高变区（互补决定区= CDR）插入到 人类的MAb框架。 这种类型的抗体构建体可以用于人类治疗和体内诊断，而不存在用鼠MAb观察到的缺点。
-
公开(公告)号：US20080206201A1
公开(公告)日：2008-08-28
申请号：US11667563
申请日：2005-11-10
CPC分类号： C07K14/005 , A01K67/0271 , A01K2267/0331 , A61K8/34 , A61K8/35 , A61K8/37 , A61K8/4953 , A61K8/922 , A61K8/97 , A61K8/99 , A61K35/768 , A61K38/1709 , A61K38/2013 , A61K38/47 , A61Q19/08 , C07K2319/33 , C12N2760/18122 , C12N2760/18132 , C12N2760/18143 , A61K2300/00
摘要： The goal of the invention is to increase the therapeutical activity of oncolytic NDV. This issue is solved by a Newcastle Disease Virus comprising a recombinant nucleic acid, wherein the nucleic acid codes for a binding protein that has a therapeutic activity when expressed by the virus-infected tumor cell. Binding proteins belong to the following group: A natural ligand or a genetically modified ligand, a recombinant soluble domain of a natural receptor or a modified version of it, a peptide-ligand, an antibody molecule and derivatives thereof or antibody-like molecules like ankyrin repeat molecules or derivatives thereof.
摘要翻译： 本发明的目标是提高溶瘤性NDV的治疗活性。 这个问题由包含重组核酸的新城疫病毒解决，其中当由病毒感染的肿瘤细胞表达时，核酸编码具有治疗活性的结合蛋白。 结合蛋白属于以下组：天然配体或遗传修饰配体，天然受体或其修饰形式的重组可溶性结构域，肽配体，抗体分子及其衍生物或抗体样分子如锚蛋白 重复分子或其衍生物。
-
48.发明授权Cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion proteins in E. coli 有权抗体，抗体片段和抗体片段融合蛋白在大肠杆菌中的细胞质表达公开(公告)号：US07314753B2
公开(公告)日：2008-01-01
申请号：US10632815
申请日：2003-08-04
申请人： Martin Opper , Klaus Bosslet , Joerg Czech
发明人： Martin Opper , Klaus Bosslet , Joerg Czech
CPC分类号： C12Y302/01031 , A61K38/00 , C07K16/00 , C07K2319/00 , C07K2319/30 , C07K2319/61 , C12N9/2434 , C12N15/62 , Y10S424/801 , Y10S435/849
摘要： The invention relates to the cytoplasmic expression of antibodies, antibody fragments and antibody fragment fusion molecules in E. coli. In particular, antibody fragment fusion molecules having an antibody moiety which is directed against tumors and an enzyme moiety which cleaves a nontoxic prodrug to give the toxic drug can be advantageously prepared in this way while retaining their respective functional properties.
摘要翻译： 本发明涉及大肠杆菌中抗体，抗体片段和抗体片段融合分子的细胞质表达。 特别地，可以有利地制备具有抗肿瘤抗体部分的抗体片段融合分子和切割无毒前药以产生毒性药物的酶部分，同时保持它们各自的功能性质。
-
公开(公告)号：US07273727B2
公开(公告)日：2007-09-25
申请号：US11135155
申请日：2005-05-23
申请人： Mathias Gehrmann , Gerhard Seeman , Klaus Bosslet , Jorg Czech
发明人： Mathias Gehrmann , Gerhard Seeman , Klaus Bosslet , Jorg Czech
CPC分类号： C12Y302/01031 , A01K2217/05 , A61K38/00 , C07K14/705 , C07K16/18 , C07K2319/00 , C07K2319/02 , C12N9/00 , C12N9/2434 , C12N15/62
摘要： The invention relates to compounds which contain an antigen binding region which is bound to at least one enzyme which is able to metabolize a compound (prodrug) which has little or no cytotoxicity to a cytotoxic compound (drug), where the antigen binding region is composed of a single polypeptide chain. It is advantageous for covalently bonded carbohydrates to be present on the polypeptide chain.
摘要翻译： 本发明涉及含有抗原结合区的化合物，所述抗原结合区与至少一种能够代谢对细胞毒性化合物（药物）具有很小或没有细胞毒性的化合物（前药）结合的酶，其中抗原结合区组成 的单个多肽链。 共价键合的碳水化合物存在于多肽链上是有利的。
-
50.发明授权Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates 失效糖基 - 依托泊苷前药，其制备方法及其与功能化肿瘤特异性酶缀合物的组合公开(公告)号：US07241595B2
公开(公告)日：2007-07-10
申请号：US10128493
申请日：2002-04-24
IPC分类号： C12P19/60
CPC分类号： B82Y5/00 , A61K38/00 , A61K47/6815 , A61K47/6851 , A61K47/6899 , A61K2039/505 , C07H17/04 , C07K16/30 , C07K16/3007 , C07K2317/24 , C07K2319/00 , C12N9/16 , C12N9/2434 , C12Y301/03001 , C12Y302/01031
摘要： The present invention relates to glycosyl-etoposide prodrugs, a process for the preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates for treating cancers.
摘要翻译： 本发明涉及糖基 - 依托泊苷前药，其制备方法及其与用于治疗癌症的官能化肿瘤特异性酶缀合物的组合的用途。
-
-
-
-
-
-
-
-
-
搜索结果
56 条记录 (耗时 0.032 秒)
